Spots Global Cancer Trial Database for A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
Official Title: A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Study ID: NCT05577715
Conditions
Interventions
Study Description
Brief Summary: The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Rocky Mountain Cancer Centers - Lone Tree, Lone Tree, Colorado, United States
Clermont Oncology Center, Clermont, Florida, United States
Mid Florida Cancer Center - Orange City, Orange City, Florida, United States
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
Norton Brownsboro Hospital, Louisville, Kentucky, United States
Maryland Oncology Hematology - Silver Spring - White Oak Cancer Center, Silver Spring, Maryland, United States
Henry Ford Hospital, Detroit, Michigan, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Texas Oncology - Arlington North, Arlington, Texas, United States
Texas Oncology - Flower Mound, Flower Mound, Texas, United States
Virginia Cancer Specialists - Fairfax, Fairfax, Virginia, United States
Local Institution - 0032, Liverpool, New South Wales, Australia
Local Institution - 0040, Wollongong, New South Wales, Australia
Local Institution - 0012, Ballarat Central, Victoria, Australia
Local Institution - 0022, Murdoch, Western Australia, Australia
Local Institution - 0036, Roeselare, BL, Belgium
Local Institution - 0024, Charleroi, WHT, Belgium
Local Institution - 0028, Providencia, SA, Chile
Local Institution - 0030, Independencia, , Chile
Local Institution - 0027, Recoleta, , Chile
Local Institution - 0023, Santiago, , Chile
Local Institution - 0037, Paris, , France
Local Institution - 0017, Rouen Cedex, , France
Local Institution - 0029, Saint Herblain, , France
Local Institution - 0015, Suresnes, , France
Local Institution - 0038, Villejuif, , France
Local Institution - 0020, Malaga, Málaga, Spain
Local Institution - 0021, Barcelona, , Spain
Local Institution - 0025, Barcelone, , Spain
Local Institution - 0018, Madrid, , Spain
Local Institution - 0019, Madrid, , Spain
Local Institution - 0026, Santiago de Compostela, , Spain
Local Institution - 0031, Seville, , Spain
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
